Oral Oncology
Volume 46, Issue 8 , Pages 622-626 , August 2010

Functional variants of COX-2 and risk of tobacco-related oral squamous cell carcinoma in high-risk Asian Indians

  • Manasi Mittal

      Affiliations

    • Department of Biotechnology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110 029, India
    • ,
  • Vaishali Kapoor

      Affiliations

    • Department of Biotechnology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110 029, India
    • ,
  • Bidhu Kalyan Mohanti

      Affiliations

    • Department of Radiation Oncology, BRA-IRCH, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110 029, India
    • ,
  • Satya Narayan Das

      Affiliations

    • Department of Biotechnology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110 029, India
    • Corresponding Author InformationCorresponding author. Tel.: +91 11 26593548; fax: +91 11 26589286.

Received 6 May 2010 ,Revised 3 June 2010 ,Accepted 5 June 2010.

References 

  1. GLOBOCAN: Cancer Incidence. Mortality and Prevalence worldwide. IARC Cancer Base No. 5, version 1.0. Lyon: IARC Press; 2002.
  2. Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA. Functional characterization of COX-2 polymorphisms. J Pharmacol Exp Therap. 2001;299:468–476
  3. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclooxygenase 2: a new class of anticancer agents?. Lancet Oncol. 2003;4:605–615
  4. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991;266:12866–12872
  5. Moraitis D, Du B, De Lorenzo MS, Boyle JO, Weskler BB, Cohen EG, et al. Levels of cyclooxygenase-2 are increased in oral mucosa of smokers: evidence for the role of epidermal growth factor receptors and its ligands. Cancer Res. 2005;65:664–670
  6. Kapoor V, Singh AK, Dey S, Sharma SC, Das SN. Circulating cycloxygenase-2 in patients with tobacco-related intraoral squamous cell carcinoma and evaluation of its peptide inhibitors as potential antitumor agent. J Cancer Res Clin Oncol. 2010;(March 6):[Epub ahead of print]
  7. Pannone G, Bufo P, Caiaffa MF, Serpico R, Lanza A, Lo Muzio L, et al. Cyclooxygenase-2 expression in oral squamous cell carcinoma. Int J Immunopathol Pharmacol. 2004;17:273–282
  8. Sawhney M, Rohatgi N, Kaur J, Shishodia S, Sethi G, Gupta SD, et al. Expression of NF kappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco. Int J Cancer. 2007;120:2545–2556
  9. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol. 2002;33:708–714
  10. Kosaka T, Miyata A, Ihara H, Hara S, Sugimoto T, Takeda O, et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem. 1994;221:889–897
  11. Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology. 2005;129:565–576
  12. Zhu W, Wei B, Shan X, Liu P. −765 G>C and 8473 T>C polymorphisms of COX-2 and cancer risk: a meta analysis based on 33 case control studies. Mol Biol Rep. 2009;37:277–288
  13. Kuersten S, Goodwin EB. The power of the 3′UTR: translational control and development. Nat Rev Genet. 2003;4:626–637
  14. Peters WH, Lacko M, Te Morche RH, Voogd AC, Oude Ophius MB, Manni JJ. COX-2 polymorphisms and the risk for head and neck cancer in white patients. Head Neck. 2009;31:938–943
  15. Lin YC, Huang HI, Wang LH, Tsai CC, Lung O, Dai CY, et al. Polymorphisms of COX-2 −765G>C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol. 2008;44:798–804
  16. Nasr HB, Chahed K, Bouaouina N, Chouchane L. PTGS (COX-2) −765G>C functional promoter polymorphism and its association with risk and lymph node metastasis in nasopharyngeal carcinoma. Mol Biol Rep. 2009;36:193–200
  17. In:  Sobin LH,  Wittekind Ch editor. UICC, TNM classification of malignant tumors. 6th ed.. New York: Wiley-Liss; 2002;
  18. Johns MB, Paulus-Thomas JE. Purification of human genomic DNA from whole blood using sodium perchlorate in place of phenol. Anal Biochem. 1989;180:276–278
  19. Baniasadi V, Narain N, Goswami R, Das SN. Promoter region −318 C/T and −1661 A/G CTLA-4 single nucleotide polymorphisms and type 1 diabetes in north Indians. Tissue Antigens. 2006;67:383–389
  20. Jeng JH, Wang YJ, Chiang BL, et al. Roles of keratinocyte inflammation in oral cancer: regulating the prostaglandin E2, interleukin-6 and TNF-α production of oral epithelial cells by areca nut extract and arecoline. Carcinogenesis. 2003;24:1301–1315
  21. Wu T. Cycloxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochem Biophys Acta. 2005;1755:135–150
  22. Konheim YL, Wolford JK. Association of a promoter variant in the inducible cyclo-oxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians. Hum Genet. 2003;113:377–381
  23. Gao J, Ke Q, Ma HX, Wang Y, Zhou Y, Hu ZB, et al. Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health A. 2007;70:908–915
  24. Chiang SL, Chen PH, Lee CH, Ko AM, Lee KW, Lin YC, et al. Up-regulation of inflammatory signallings by areca nut extract and role of cyclooxygenase-2 −1195G>A polymorphism reveal risk of oral cancer. Cancer Res. 2008;68:8489–8498
  25. Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis. 2004;25:961–966
  26. Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Brit J Cancer. 2004;90:1760–1764
  27. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol. 2002;22:1631–1636
  28. Szczeklik W, Sanak M, Szczeklik A. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol. 2004;114:248–253
  29. Park JM, Choi JE, Chae MH, Lee WK, Cha SI, Son JW, et al. Relationship between cyclooxygenase 8473T>C pollymorphism and risk of lung cancer: a case-control study. BMC Cancer. 2006;6:70
  30. Campa D, Hashibe M, Zaridze D, Szeszenia-Dabrowska N, Mates IN, Janout V, et al. Association of common polymorphisms in inflammatory genes with risk of developing cancer of the upper aerodigestive tract. Cancer Cause Control. 2007;18:449–455

PII: S1368-8375(10)00185-5

doi: 10.1016/j.oraloncology.2010.06.002

Oral Oncology
Volume 46, Issue 8 , Pages 622-626 , August 2010

Article Tools

* Image Usage & Resolution